hodgkin's%20lymphoma
HODGKIN'S LYMPHOMA

Hodgkin's lymphoma is a malignancy that arises from germinal center B cell.

Histologically, there is a presence of multinucleated giant cells in a mixed inflammatory background.

It is also known as Hodgkin's disease, Hodgkin lymphoma or Hodgkin disease.

It commonly affects individuals ages 15-30 years old and those 55 years old and above.

The key morphologic characteristics include presence of Reed-Sternberg cells and lymphocyte-predominant cells.

Hodgkin's%20lymphoma Signs and Symptoms

Introduction

  • Also known as Hodgkin’s disease, Hodgkin lymphoma, or Hodgkin disease
  • Commonly affects ages 15-30 years old, & individuals 55 years old & above

Definition

  • A malignancy involving the lymph nodes & the lymphatic system

Etiology

  • Viruses (eg Epstein-Barr virus)
  • Positive family history of hematopoietic malignancy & autoimmune/chronic inflammatory diseases
  • Positive family history of Hodgkin's lymphoma

Prognostic Factors

  • Presence of the following reduces the survival rate by 7-8%/year:
    • Age ≥45 years old
    • Gender: Males are at increased risk
    • Patients diagnosed with stage IV disease
    • Albumin level: <4 g/dL
    • Hemoglobin (Hgb) level: <10.5 g/dL
    • Leukocytosis [White blood cell (WBC) ≥15,000/mm3]
    • Lymphocytopenia (Lymphocyte count <8% of WBC &/or <600/mm3)

Signs and Symptoms

  • Assess patient’s performance status based on the clinical presentation
  • Painless peripheral adenopathies (commonly within the cervical or supraclavicular areas)
  • Chest pain or pain within the mediastinum
  • Pain at a nodal site after drinking alcohol
  • Chronic pruritus
  • Systemic B symptoms
    • Unexplained fever (>38oC/100.4oF)
    • Drenching night sweats
    • Weight loss (>10% of baseline) within 6 months of diagnosis
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 09 Oct 2020

Individualized starting dose (ISD) of maintenance niraparib improves progression-free survival (PFS) vs placebo in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC), results of the NORA trial have shown.

Dr Margaret Shi, 14 May 2020
Pembrolizumab monotherapy improves overall survival (OS) and cancer control compared with platinum-based chemotherapy in patients with untreated locally advanced or metastatic programmed death-ligand 1 (PD-L1)–positive non-small-cell lung cancer (NSCLC) regardless of STK11 or KEAP1 mutation status, according to results of the phase III KEYNOTE-042 study.